A Novel FLT3 Y842D Mutation Carriers a Potentially Highly Sensitivity to Midostaurin? Case Report and Literature Review

He Shujiao  
Shenzhen University

Zhang minjie  
baoding city maternal and child health hospital

Li jieying  
Shenzhen University

Zhao weiqiang  
Shenzhen University

Yu li  
Shenzhen University

Pang yanbin (✉ 1113911251@qq.com)  
Shenzhen University

Short report

Keywords: FMS-like tyrosine kinase 3, acute myeloid leukemia, midostaurin, differentiation syndrome

DOI: https://doi.org/10.21203/rs.3.rs-197301/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Y842D mutation in the activation loop of FLT3 caused a strong resistance to Sorafenib in vitro, whether this kind of mutation would exert clinical significance on acute myeloid leukemia (AML) patients remain to be clarified.

**Case presentation:** Here, we described a novel type of activating mutation (Y842D) within the kinase domain of FLT3 in a pregnancy with de novo acute myeloid leukemia. Following induction failure with standard dose of idarubicin and cytarabine (IA), the patient received a re-induction combined with midostaurin, a promising agent targeting mutant-FLT3, and IA regimen. Fortunately, morphological remission was achieved. During the period of midostaurin treatment, the patient exhibited a symptom which was quite similar to the differentiation syndrome which disappeared following the treatment with methylprednisolone.

**Conclusions:** Clinically, we showed for the first time that Y842D, a novel activating mutation in the activation loop of FLT3, tend to be a sensitive mutation form to midostaurin in acute myeloid leukemia patients.

Introduction

FMS-like tyrosine kinase 3 (FLT3) is a type 3 receptor tyrosine kinase. Certain alteration of this protein can constitutively active receptor tyrosine kinase causing uncontrolled proliferation, reduced apoptosis, and malignant transformation of myeloid cells[1]. Thus, mutant FLT3 is well known as a promising target for molecular therapy in acute myeloid leukemia (AML)[1, 2]. FLT3 mutation occurred in 30% of de novo AML, with internal tandem duplication (FLT3-ITD) in juxtamembrane domain observed in 75% of mutant patients and point mutation within the activation loop of tyrosine kinase domain (FLT3-TKD) in the rest of 25% patients[3]. Based on previous clinical research, even hematopoietic stem cell transplantation (HSCT) cannot reverse the adverse effect of FLT3-ITD on AML patients[4]. Given the rare probability of FIT3-TKD mutation in AML, it is reasonable that no large sample randomized controlled clinical trial was reported. However, the current results shown that the negative impact of TKD mutation seems comparable to that of ITD with regard to disease free survival time (DFS) in patients with AML[5].

D835 was the most common mutation site in FLT3-TKD, other types of mutation such as 836 and 840, could also be found in AML patients[6]. Y842 was a key residue in regulating exon 20 of FLT3, which formed a hydrogen bond with Asp811, the latter in turn was linked to Arg834 through an ion pair which leads to closed (inactive) conformation of the FLT3 activation loop[7]. When 842 tyrosine residue was substituted by cysteine (FLT3-Y842C), the FLT3 activation loop switched from closed conformation to the open (active) conformation and led to constitutive activation of FLT3 and signal transducer and activator of transcription 5 (STAT-5) tyrosine phosphorylation, thus contributed to malignant transformation of myeloid cells[8]. Consequently FLT3-Y842C was a potentially sensitive mutation type to sorafenib, a multitargeted kinase inhibitor which inhibited activation of FLT3 signaling and suppressed proliferation.
of leukemia cells in preclinical models\cite{8}. However, in vitro analyses showed replacement of 842 tyrosine residue with Aspartic acid (Y842D) possessed different biological characteristics comparing with Y842C, as Y842D mutant cells were much more resistant to sorafenib\cite{9}.

Here, we described the characterization of a novel type of activating mutation (Y842D) within the kinase domain of FLT3. To the best of our knowledge, this was the first reported de novo novel case with mutant Y842D and who achieved complete remission (CR) after re-induction with midostaurin and IA regimen (idarubicin and cytarabine). Our result showed that Y842D in FLT3-ITD tend to be a sensitive mutation form to chemotherapy regimen containing midostaurin.

**Case Presentation**

A 29-year-old, gravida 1 parity 0 woman at 18 weeks of pregnancy admitted to our hospital for intermittent fever for a week on August 30th, 2020. Routine blood test (RBT) showed white blood cells (WBC) count of 203.39×10^9/L (normal range: 4.0–10×10^9/L), hemoglobin (Hb) count of 78g/L(normal range: 120-175g/L), and platelets (PLT) count of 96×10^9/L (normal range: 100–350×10^9/L). Notably, a month ago, on July 21st, 2020, the patient has undergone RBT during her pregnancy examination which revealed WBC of 7.63×10^9/L, Hb of 121g/L, and PLT of 193×10^9/L. In just 40 days, the patient's white blood cells increased by 25.66 times (Fig. 1). Meanwhile, blood cell smear indicated 95% blast cells in peripheral blood, bone marrow smear showed extremely active hyperplasia with 91% blast cells, the proliferation of granulocytes, macrophages, megakaryocytes and erythroblasts were significantly inhibited. Blast cells were strongly positive for esterase staining which could be inhibited by sodium fluoride. Flow cytometry revealed that myeloid blasts exhibited monocytic differentiation tendency (CD34-, CD117-, CD33+, CD64+, CD4 dim, CD13-, HLA-DR+). Karyotypic analysis of bone marrow cells expressed the translocation of t (8;22) (p11.2; q13) (Fig. 2). Gene mutation detection showed that FLT3 point mutation T2524G which led to replacement of alanine by aspartic acid at site 842 within the receptor tyrosine kinase domain (FT3-TKD, Y842D), allelic ratios was 36.4%. Meanwhile, another mutant gene, KMT2D, was detected with allelic ratios 46.6%. Comprehensively, the patient was diagnosed as AML-M5 and classified into unfavorable category according to French–American–British (FAB) classification systems and 2019 version of National Comprehensive Cancer Network (NCCN)\cite{10}.

Hydroxyurea was used to dealing with hyperleukocytosis and artificial abortion was conducted prior to induction chemotherapy. On September 14, first induction therapy was carried out using cytarabine (100 mg/m^2/d, d1-7) and idarubicin (10 mg/m^2/d, d1-3). On October 12, 8.8% primitive monocytes and 30% immature monocytes still resided in bone marrow according to bone marrow smear analysis. Meanwhile flow cytometry revealed 35.2% myeloid blasts showing monocytic differentiation tendency. To obtain better clinical efficacy, FLT3-ITD inhibitor midostaurin (50mg, q12h, d8-21) combined with IA regimen was adopted in the re-induction therapy on October 14. On October 30, 10 days after midostaurin treatment, the patient suffered from fever, body temperature gradually raising from 38.1 to 40.2 degrees Celsius. At the same time, skin rash accompanied by pruritus spread from both lower extremities rapidly to the whole.
body, including face, and continued to progress 3 to 4 days (Fig. 3). Blood biochemistry test revealed glutamic-pyruvic transaminase and glutamic oxalacetic transaminase reached 89U/L and 160U/L, respectively. Following treatment with methylprednisolone for a week, on November 6 patient gradually recovered from skin rash. November 11, no primitive monocytes and immature monocytes were found in bone marrow, meanwhile minimal residual disease (MRD) revealed myeloid blast cells account for less than 0.1% of non-erythroid cells of the bone marrow, namely morphological remission was achieved. Considering the negative effect of FLT3-TKD on clinical prognosis, another cycle of consolidation therapy with cytarabine (1.5g/m2, q12h, d1, 3, 5) and midostaurin was conducted, then the patient was subjected to hematopoietic stem cell transplantation (HSCT). Her whole disease course and clinical outcomes were summarized in Fig. 4.

Discussion

The past 30 years have witnessed the thriving development of molecular related fundamental researches on hematopoietic cells, which in turn greatly enriched therapeutic strategies for acute myeloid leukemia and led the priority treatment of leukemia entered the era of molecularly guided precision therapy\cite{11–13}. Take the treatment of acute promyelocytic leukemia (APL) as an example, application of all-trans retinoic acid and arsenous cured about 90% of APL patients\cite{14}. Undoubtedly, therapies based on genetics and epigenetics changes played an increasing role in the treatment of non-M3 AML. In combination with standard 3 + 7 regimen, molecular targeted agents were supposed to improve remission rate of induction therapy effectively and provide more opportunities for subsequent HSCT\cite{14}.

Mutant FLT3 contained two kinds of mutation forms, internal tandem duplication (ITD) in juxtamembrane domain and point mutation within the activation loop of tyrosine kinase domain (TKD)\cite{2}. FLT3 mutation occurred in 30% of de novo AML patients and accounted for the most predominant mutation type in AML\cite{1}. Notably, FLT3-ITD was considered as an independent unfavorable risk factor in AML, for patients with FLT3-ITD always be resistant to chemotherapy and present a higher relapse rate and more early death cases. Though the clinical significance of FLT3-TKD on AML remains to be confirmed due to relative rare incidence, meta-analysis showed that FLT3-TKD exerted similar unfavorable effect on AML as FLT3-ITD\cite{5}.

Generally, patients with mutant FLT3 frequently accompanied with hyperleukocytosis\cite{15}. Nevertheless, the effect of each mutation form, particularly Y842D, on clinical phenotype remains to be clarified. Back to the case we reported, in just 40 days, patient's white blood cell count raised from $7.63 \times 10^9/L$ to $203.39 \times 10^9/L$. The doubling time was as short as 8.45 days, which was very similar to the clinical characterization of patients with FLT3-ITD. It was generally known that consecutive activation of FLT3 and downstream signaling pathways resulted in uncontrolled proliferation of hematopoietic cells. According to Kindler T\cite{8} research, point mutation at Y842 altered the conformation of FLT3 receptor tyrosine kinase domain and drove the formation of activation loop. Mediated by downstream signaling pathway, including STAT5, myeloid cells with Y842C acquired the ability to proliferate indefinitely. Murine
32D cells transfected with human FLT3-Y842C showed activated FTL3 and STAT5 signaling pathway which can be inhibited by FLT3 inhibitor (N-benzoyl staurosporine, PKC412). The above results demonstrated that mutation of FLT3-Y842 played a critical role in the development of AML. Comprehensively, it was reasonable to deduced that hyperleukocytosis of the patient might attribute to continuous activation of FLT3 caused by Y842D.

Another important biological characteristic of FLT3-Y842D mutant AML cells was that they may be resistant to certain FLT3 inhibitors. Through cultivating cells with different gradient concentrations of FLT3 inhibitors, researchers successfully screened out FLT3 inhibitors-resistant FTL3 mutant cells. Base on this screening experiment, von Bubnoff N and his colleagues found that, at the same concentration, myeloid cells with FLT3-Y842D was resistant to sorafenib instead of midostaurin [9]. This may be the reason why sorafenib was only used in the treatment of FLT3-ITD mutant AML patients[16]. In a phase III, randomized control clinical trial, researchers compared induction therapy effect of daunorubicin (60mg/m2, d3-5), cytarabine (20mg/m2, d1-7) with or without midostaurin in 717 AML patients with mutant FLT3, including 162 patients with FLT3-TKD. Statistically, the median overall survival time in midostaurin group was 74.7 months (95%CI:31.5-not achieved), significantly better than 25.6 months (95%CI:18.6–42.9) in placebo group. Meanwhile, the incidence of adverse events between the above two groups revealed no significant difference[14]. That was also a critical reason for clinical application of midostaurin in AML patients with FLT3 mutation and why we chose midostaurin, cytarabine, and idarubicin as re-induction regimen in this case. 23 days after re-induction, morphological remission was achieved, which might indicate that patient with FLT3-Y842D potentially be sensitive to midostaurin.

The third characteristic of this case was that the patient presented with differentiation syndrome on the 10th day of midostaurin treatment. Red nodular rash firstly appeared in symmetrical parts of both lower limbs, accompanied by pruritus and fever. This type of rash often occured in patients treated with selective FLT3 inhibitors, such as cuzatinib, gliptinib[17,18]. Pathologically, FLT3 inhibitors induced differentiation of primordial cells into neutrophils, this rash was exactly caused by the infiltration of neutrophils in deep skin and subcutaneous tissues[18]. Take AML patients who received cuzatinib monotherapy as an example, though the proliferative degree of nucleated cells did not alter significantly 29 days after therapy, the proportions of cells with different degrees of differentiation changed a lot. The proportion of primordial cells decreased from 77–6%, the proportion of myelocyte, metamyelocyte, and neutrophils raised from 9–57%. Since the mutation frequency of FLT3-ITD did not changed, it was sufficiently to conclude that the mature neutrophils derived from differentiation of primordial cells[17]. Mc Mahon cm and his colleague evaluated the validity of gliptinib in 21 AML patients with FLT3 mutation, 10 patients suffered from differentiation syndrome during treatment. The overall survival time and morphological remission rate of these 10 patients was much more worse than that of the other 11 ones[19]. Similar with the prevention of retinoic acid-induced differentiation syndrome, it was confirmed that, combination of glucocorticoid with FLT3 inhibitor not only upregulated the expression of proapoptotic protein Bim, but also induced leukemia cell apoptosis by promoting the degradation of antiapoptotic protein Mcl-1[20]. Therefore, FLT3 inhibitor combined with glucocorticoid in the prevention of
FLT3 inhibitor induced differentiation syndrome needed further study. In addition, patient in this report did not concurrent with rearrangement of NPM1 or CBF genes, which were also regarded as important unfavorable prognostic factors in AML[21]. To sum up, it was sensible to treat this patient with allogeneic-HSCT as soon as possible, and maintenance therapy after transplantation with midostaurin would further improve the clinical outcome.

In conclusion, this case showed that FLT3-Y842D mutation was a new activating mutation form of FLT3 in AML. Patients with this mutation tend to be sensitive to midostaurin. In the process of midostaurin treatment, we should be alert to the existence of differentiation syndrome, once observed, glucocorticoid should be used as soon as possible. It is notable that allogeneic hematopoietic stem cell transplantation should be conducted since patients achieved complete remission as soon as possible.

Declarations

ETHICS STATEMENT

Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.

Availability of data and materials

The raw data supporting our findings can be requested from the corresponding author.

Ethics approval and consent to participate

Not applicable.

AUTHOR CONTRIBUTIONS

MJ composed the manuscript and performed literature review. SJ did the acquisition and analysis of laboratory data for the work. JY and WQ did the acquisition and analysis of laboratory data for the work. YL critically revised and interpreted the data. PY took care of the patient from the clinical point of view. MJ and SJ wrote the manuscript while YP fully revised and improved it. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Ambinder AJ, Levis M. Potential targeting of FLT3 AML. Haematologica 2020.
2. Eguchi M, Minami Y, Kuzume A, Chi S. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines 2020, 8(8).

3. Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol 2019, 187(4): 488-501.

4. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012, 30(7): 735-741.

5. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005, 19(8): 1345-1349.

6. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcuccio G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111(3): 1552-1559.

7. Kazi JU, Chougule RA, Li T, Su X, Moharram SA, Rupar K, Marhall A, Gazi M, Sun J, Zhao H, Ronnstrand L. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. Cell Mol Life Sci 2017, 74(14): 2679-2688.

8. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 2005, 105(1): 335-340.

9. von Bubnoff N, Engh RA, Aber E, Sanger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009, 69(7): 3032-3041.

10. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcuccio G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, Ocn, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019, 17(6): 721-749.

11. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012, 26(9): 2061-2068.
12. Stein EM, Dinardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019, 133(7): 676-687.

13. Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res 2018, 24(10): 2294-2303.

14. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017, 377(5): 454-464.

15. Dumas PY, Bertoli S, Berard E, Largeaud L, Bidet A, Delabesse E, Leguay T, Leroy H, Gadaud N, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, de Grande AC, Pigneux A, Recher C. Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. Cancers (Basel) 2020, 12(8).

16. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanss C, Repp R, Heits F, Dürk H, Hase J, Klut I-M, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetteljig K, Kramer M, Berdel WE, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. The Lancet Oncology 2015, 16(16): 1691-1699.

17. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 2012, 120(20): 4205-4214.

18. Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood 2013, 122(2): 239-242.

19. McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv 2019, 3(10): 1581-1585.

20. Gebru MT, Atkinson JM, Young MM, Zhang L, Tang Z, Liu Z, Lu P, Dower CM, Chen L, Annageldiyev C, Sharma A, Imamura Kawasawa Y, Zhao Z, Miller BA, Claxton DF, Wang HG. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood 2020, 136(9): 1067-1079.
21. Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Dohner K, Stone RM, Dohner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a sub analysis from the RATIFY trial. Blood Adv 2020, 4(19): 4945-4954.